89 related articles for article (PubMed ID: 21061438)
1. The L1 major capsid protein of HPV16 differentially modulates APC trafficking according to the vaccination or natural infection context.
Herman L; Hubert P; Herfs M; Kustermans G; Henrotin Y; Bousarghin L; Boniver J; Delvenne P
Eur J Immunol; 2010 Nov; 40(11):3075-84. PubMed ID: 21061438
[TBL] [Abstract][Full Text] [Related]
2. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape.
Fahey LM; Raff AB; Da Silva DM; Kast WM
J Immunol; 2009 Nov; 183(10):6151-6. PubMed ID: 19864613
[TBL] [Abstract][Full Text] [Related]
3. Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation.
de Witte L; Zoughlami Y; Aengeneyndt B; David G; van Kooyk Y; Gissmann L; Geijtenbeek TB
Immunobiology; 2007; 212(9-10):679-91. PubMed ID: 18086370
[TBL] [Abstract][Full Text] [Related]
4. Silencing of E7 oncogene restores functional E-cadherin expression in human papillomavirus 16-transformed keratinocytes.
Caberg JH; Hubert PM; Begon DY; Herfs MF; Roncarati PJ; Boniver JJ; Delvenne PO
Carcinogenesis; 2008 Jul; 29(7):1441-7. PubMed ID: 18566017
[TBL] [Abstract][Full Text] [Related]
5. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Langerhans cell maturation by human papillomavirus type 16: a novel role for the annexin A2 heterotetramer in immune suppression.
Woodham AW; Raff AB; Raff LM; Da Silva DM; Yan L; Skeate JG; Wong MK; Lin YG; Kast WM
J Immunol; 2014 May; 192(10):4748-57. PubMed ID: 24719459
[TBL] [Abstract][Full Text] [Related]
7. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
10. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
[TBL] [Abstract][Full Text] [Related]
12. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity].
Wei MX; Li SW; Huang B; Shen WT; Su YZ; Zhang CH; Gu Y; Du HL; Zhang J; Xia NS
Bing Du Xue Bao; 2009 Jul; 25(4):245-50. PubMed ID: 19769155
[TBL] [Abstract][Full Text] [Related]
13. In vivo mechanisms of vaccine-induced protection against HPV infection.
Day PM; Kines RC; Thompson CD; Jagu S; Roden RB; Lowy DR; Schiller JT
Cell Host Microbe; 2010 Sep; 8(3):260-70. PubMed ID: 20833377
[TBL] [Abstract][Full Text] [Related]
14. Rectal and vaginal immunization of mice with human papillomavirus L1 virus-like particles.
Fraillery D; Zosso N; Nardelli-Haefliger D
Vaccine; 2009 Apr; 27(17):2326-34. PubMed ID: 19428847
[TBL] [Abstract][Full Text] [Related]
15. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors.
Nieto K; Kern A; Leuchs B; Gissmann L; Müller M; Kleinschmidt JA
Antivir Ther; 2009; 14(8):1125-37. PubMed ID: 20032542
[TBL] [Abstract][Full Text] [Related]
16. Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 Virus-like particles.
García-Piñeres A; Hildesheim A; Dodd L; Kemp TJ; Williams M; Harro C; Lowy DR; Schiller JT; Pinto LA
Clin Vaccine Immunol; 2007 Aug; 14(8):984-9. PubMed ID: 17596432
[TBL] [Abstract][Full Text] [Related]
17. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Stanley M; Lowy DR; Frazer I
Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
[TBL] [Abstract][Full Text] [Related]
18. HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice.
Berg M; Gambhira R; Siracusa M; Hoiczyk E; Roden R; Ketner G
Vaccine; 2007 Apr; 25(17):3501-10. PubMed ID: 16914239
[TBL] [Abstract][Full Text] [Related]
19. Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells.
Yan M; Peng J; Jabbar IA; Liu X; Filgueira L; Frazer IH; Thomas R
Virology; 2004 Jul; 324(2):297-310. PubMed ID: 15207617
[TBL] [Abstract][Full Text] [Related]
20. Reversal of human papillomavirus-specific T cell immune suppression through TLR agonist treatment of Langerhans cells exposed to human papillomavirus type 16.
Fahey LM; Raff AB; Da Silva DM; Kast WM
J Immunol; 2009 Mar; 182(5):2919-28. PubMed ID: 19234187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
